Monsoon illnesses & flu surge lift drug demand

Monsoon illnesses and a significant rise in H1N1 cases are driving a surge in demand for acute therapies and flu vaccines. Sales of anti-infectives and antibacterials saw a 12% month-on-month increase in July, with flu vaccine sales nearly tripling year-on-year in August, leading to supply challenges in several cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ak4YGcN
via IFTTT

Read More

Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impact

Sun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affordable for low-income Americans. Analysts believe the financial impact on Sun Pharma will be minimal. The company's US revenue contribution is significant, reinforcing its growth strategy. This pact recognizes Sun Pharma's investment in the American market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72ErY3T
via IFTTT

Read More

Permira to buy 25.71% in Cloudnine Hospitals parent: CCI filing

Permira, a leading global private equity firm, is ready to buy a significant stake in Cloudnine Hospitals, which places the parent company's valuation at approximately eleven thousand crore rupees. This acquisition involves purchasing the stake from existing investor True North Capital. The deal awaits appropriate regulatory clearances, and Cloudnine is also exploring acquisitions of further hospital ventures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gIk8GKT
via IFTTT

Read More

Sun Pharma to extend MFN pricing to US state Medicaid programmes

Sun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Recent US launches include Leqselvi for severe alopecia areata and Unloxcyt for advanced cutaneous squamous cell carcinoma, strengthening its presence in dermatology and cutaneous oncology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4aMSKxO
via IFTTT

Read More

Delhi HC orders forensic audit of Fortis, Singh brothers' Rs 4,666-crore trail

The Delhi High Court ordered a forensic audit of Fortis Healthcare transactions. This audit will examine dealings with IHH Healthcare Berhad and RHT Health Trust. It will also probe transactions involving the Singh brothers and Religare Group companies. The court seeks to trace the movement of shares and funds. This comprehensive audit must be completed within six months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QbyhGro
via IFTTT

Read More

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These initiatives aim to reduce reliance on foreign suppliers and lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WK9DlJh
via IFTTT

Read More

Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial

Zydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver disease linked to metabolic disorders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6rsDj4
via IFTTT

Read More